A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa

[1] Baeten JM(2012)Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 399-410

[2] Donnell D(2018)Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town trial): a randomised, open-label, phase 2 trial The lancet HIV 5 e68-e78

[3] Ndase P(2015)Tenofovir-based preexposure prophylaxis for HIV infection among African women N Engl J Med 372 509-518

[4] Mugo NR(2012)Preexposure prophylaxis for HIV infection among African women N Engl J Med 367 411-422

[5] Campbell JD(2010)Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science (New York, NY) 329 1168-1174

[6] Wangisi J(2016)Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial Lancet (London, England) 387 53-60

[7] Bekker LG(2013)Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial AIDS (London, England) 27 2155-2160

[8] Roux S(2012)Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N Engl J Med 367 423-434

[9] Sebastien E(2010)Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587-2599

[10] Yola N(2013)Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial Lancet (London, England) 381 2083-2090

[1] Baeten JM(2012)Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 399-410

[2] Donnell D(2018)Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town trial): a randomised, open-label, phase 2 trial The lancet HIV 5 e68-e78

[3] Ndase P(2015)Tenofovir-based preexposure prophylaxis for HIV infection among African women N Engl J Med 372 509-518

[4] Mugo NR(2012)Preexposure prophylaxis for HIV infection among African women N Engl J Med 367 411-422

[5] Campbell JD(2010)Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science (New York, NY) 329 1168-1174

[6] Wangisi J(2016)Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial Lancet (London, England) 387 53-60

[7] Bekker LG(2013)Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial AIDS (London, England) 27 2155-2160

[8] Roux S(2012)Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N Engl J Med 367 423-434

[9] Sebastien E(2010)Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587-2599

[10] Yola N(2013)Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial Lancet (London, England) 381 2083-2090